Oramed Pharmaceuticals (ORMP)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	42.10 mm	42.10 mm	42.10 mm	42.10 mm	42.10 mm	42.10 mm
Cash burn (monthly)	14.22 mm	(no burn)	6.17 mm	(no burn)	2.37 mm	659.92 k
Cash used (since last report)	40.05 mm	n/a	17.38 mm	n/a	6.67 mm	1.86 mm
Cash remaining	2.06 mm	n/a	24.72 mm	n/a	35.44 mm	40.25 mm
Runway (months of cash)	0.1	n/a	4.0	n/a	15.0	61.0

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

ORMP institutional ownership history Ownership history

10.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	32	47	-31.9%
Opened positions	11	46	-76.1%
Closed positions	26	1	+2500.0%
Increased positions	5	0	NEW
Reduced positions	6	0	NEW

13F shares	Current	Prev Q	Change
Total value	7.24 bn	13.52 bn	-46.5%
Total shares	4.17 mm	6.14 mm	-32.1%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Murchinson	1.70 mm	$4.37 bn	+23.2%
Slager David Mark	1.34 mm	$5.70 mm	0.0%
Two Sigma Advisers	259.10 k	$665.89 mm	-1.7%
BAC Bank of America	173.24 k	$445.23 mm	NEW
Two Sigma Investments	150.37 k	$386.44 mm	+11.8%
Susquehanna International	125.83 k	$323.38 mm	-63.5%
Squarepoint Ops	81.76 k	$210.12 mm	NEW
STT State Street	59.26 k	$152.30 mm	+1.9%
Jane Street	56.07 k	$144.10 mm	-35.1%
MS Morgan Stanley	45.43 k	$116.77 mm	+1.6%

Largest transactions	Shares	Bought/sold	Change
BML Capital Management	0.00	-844.50 k	EXIT
Boothbay Fund Management	0.00	-689.75 k	EXIT
Murchinson	1.70 mm	+320.50 k	+23.2%
RAT Rathbone Brothers	0.00	-289.80 k	EXIT
Susquehanna International	125.83 k	-218.61 k	-63.5%
BAC Bank of America	173.24 k	+173.24 k	NEW
Renaissance Technologies	0.00	-122.10 k	EXIT
BLK BlackRock	0.00	-89.30 k	EXIT
Qube Research & Technologies	107.00	-88.09 k	-99.9%
Squarepoint Ops	81.76 k	+81.76 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ORMP insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	#Shares	#Remaining
7 Nov 24	Avraham Gabay	Common Stock	Grant	Acquire A	No	No	30,000	170,040
7 Nov 24	Kidron Miriam	Common Stock	Grant	Acquire A	No	No	30,000	793,666
7 Nov 24	Kidron Nadav	Common Stock	Grant	Acquire A	No	No	45,000	1,826,098
7 Nov 24	Joshua Hexter	Common Stock	Grant	Acquire A	No	No	30,000	511,833
21 Jun 24	Avraham Gabay	Common Stock	Grant	Acquire A	No	No	140,040	0

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Scilex Announces Voluntary $13.2M Early Payment On Oramed Note, Full Retirement Set For March 2025

16 Dec 24

Scilex Holding Company (NASDAQ:SCLX, "Scilex" or the "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing the treatments for obesity, neurodegenerative,

Scilex Holding Company Announces Signing Of A $50M Registered Convertible Financing To Purchase Up To 7.5M Shares Of Common Stock In A Registered Direct Offering, To Refinance And Restructure Existing Debt & Strengthen Financial Profile

7 Oct 24

Affiliates of Murchinson, 3i LP, and existing senior debt holder, Oramed Pharmaceuticals, Inc. ("Oramed"), are expected to participate in the $50 million convertible note offering, which is expected to close on or about October 7, 2024.

Press releases

From Benzinga Pro

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt

7 Oct 24

NEW YORK, Oct. 7, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today